Skip to content

References: Medicine for the Gut-Brain Axis

  1. About C. diff - Centers for Disease Control and Prevention - A plain-language overview of C. difficile infection: symptoms, who is at risk, and how antibiotics raise the risk. Source for the "almost half a million infections" figure in Section 17.2.

  2. REBYOTA (fecal microbiota, live-jslm) - US Food and Drug Administration - The FDA's product page, with the exact approved use and links to the November 30, 2022 approval letter and review documents.

  3. FDA Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of Clostridioides difficile Infection - US Food and Drug Administration, April 26, 2023 - The Vowst announcement, including the trial results (12.4% vs 39.8% recurrence) and the risks of products made from human stool.

  4. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile - Minkoff NZ, et al. Cochrane Database of Systematic Reviews, 2023 - A systematic review of 6 randomized trials showing FMT clears recurrent C. diff in adults with healthy immune systems. Its plain-language summary is a good model of honest evidence reporting.

  5. Fecal transplantation for treatment of inflammatory bowel disease - Imdad A, et al. Cochrane Database of Systematic Reviews, 2023 - The review behind Section 17.6's conclusion that FMT for ulcerative colitis is promising but low certainty, and very uncertain for Crohn's disease.

  6. Understanding Unapproved Use of Approved Drugs "Off Label" - US Food and Drug Administration - Explains what FDA approval means, why doctors sometimes prescribe drugs off-label, and what questions patients can ask.

  7. Step 3: Clinical Research - US Food and Drug Administration - The FDA's description of clinical trial phases 1 to 4, including how many people take part and what share of drugs move on to the next phase.

  8. Premarket Approval P970003/S050: VNS Therapy System for depression - US Food and Drug Administration device database - The official record of the July 15, 2005 approval of vagus nerve stimulation for treatment-resistant depression, with the exact indication. Links from it lead to the original 1997 epilepsy approval.

  9. Summary of Safety and Effectiveness Data: SetPoint System (PMA P240039) - US Food and Drug Administration, 2025 - The FDA's summary of the evidence behind the July 30, 2025 approval of vagus nerve stimulation for rheumatoid arthritis, including the RESET-RA trial results. Long and technical; the indication and effectiveness sections are the most readable.

  10. De Novo DEN150048: gammaCore Non-invasive Vagus Nerve Stimulator - US Food and Drug Administration device database - The record of the April 14, 2017 De Novo authorization of gammaCore for cluster headache, a useful example of an FDA authorization rather than an approval.

  11. The inflammatory reflex - Tracey KJ. Nature, 2002 - The influential review proposing that the nervous system reflexively controls inflammation, the idea behind vagus nerve stimulation for rheumatoid arthritis and the field of bioelectronic medicine.

  12. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS) - Ford AC, et al. The Lancet, 2023 - The 463-person randomized trial analyzed in this chapter's "How to read a gut-brain claim" box, showing low-dose amitriptyline helped IBS symptoms more than placebo.